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A B S T R A C T   
The purpose of the “Micronuclei and Disease” special issue (SI) is to: (i) Determine the level of evidence for association 
of micronuclei (MN), a biomarker of numerical and structural chromosomal aberrations, with risk of specific diseases in 
humans; (ii) Define plausible mechanisms that explain association of MN with each disease; (iii) Identify knowledge 
gaps and research needed to translate MN assays into clinical practice. 
The “MN and Disease” SI includes 14 papers. The first is a review of mechanisms of MN formation and their 
consequences in humans. 11 papers are systematic reviews and/or meta-analyses of the association of MN with 
reproduction, child health, inflammation, auto-immune disease, glycation, metabolic diseases, chronic kidney 
disease, cardiovascular disease, eleven common cancers, ageing and frailty. The penultimate paper focuses on 
effect of interventions on MN frequency in the elderly. A road map for translation of MN data into clinical 
practice is the topic of the final paper. 
The majority of reviewed studies were case-control studies in which the ratio of mean MN frequency in disease 
cases relative to controls, i.e. the mean ratio (MR), was calculated. The mean of these MR values, estimated by 
meta-analyses, for lymphocyte and buccal cell MN in non-cancer diseases were 2.3 and 3.6 respectively, and for 
cancers they were 1.7 and 2.6 respectively. The highest MR values were observed in studies of cancer cases in 
which MN were measured in the same tissue as the tumour (MR = 4.9–10.8). 
This special issue is an important milestone in the evidence supporting MN as a reliable genomic biomarker of 
developmental and degenerative disease risk. These advances, together with results from prospective cohort 
studies, are helping to identify diseases in which MN assays can be practically employed in the clinical setting to 
better identify high risk patients and to prioritise them for preventive therapy.  
Abbreviations: AGEs, advanced glycation end products; BMI, body mass index; BUC, buccal; CAD, coronary artery disease; CBMN, cytokinesis-block micronucleus; 
CDC, cervix derived cells; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disorder; cGAS-STING, cyclic GMP-AMP Synthase-Stimulator of 
Interferon Genes; HbA1c, glycated haemoglobin; IBD, inflammatory bowel disease; LYM, lymphocyte; MN, micronuclei; MR, mean ratio; NPB, nucleoplasmic bridges; 
NBUD, nuclear buds; RBC, red blood cell; RCT, randomised controlled trial; SEM, standard error of the mean; UDC, urine derived cells. 
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1. Introduction 
Micronuclei (MN) are produced in cells from malsegregation of 
chromosome fragments and/or whole chromosomes during mitosis and 
are considered to be one of the best validated biomarkers of chromo-
some instability [1]. They are also indicators of defective DNA replica-
tion and repair, mitotic errors caused by genetic defects, exposure to 
environmental or endogenous genotoxins, nutritional deficiency or 
excess, and genotoxic life-style factors. 
Furthermore, MN increase with aging and are associated cross- 
sectionally and prospectively with infertility, pregnancy complica-
tions, developmental defects, obesity, diabetes, kidney disease, cardio-
vascular disease, a wide-range of cancers, cognitive impairment and 
neurological disorders such as Parkinson’s disease and Alzheimer’s 
disease [2]. The frequency of MN is modifiable by appropriate diet and 
life-style intervention and could prove to be an important biomarker for 
monitoring the efficacy and safety of such interventions aimed at 
improving health at the fundamental genome level [3]. 
Other cytogenetic biomarkers associated with MN are nucleoplasmic 
bridges (NPB) which originate from dicentric chromosomes caused by 
mis-repair of DNA breaks or telomere end fusions, and nuclear buds 
(NBUD) which originate from extrusion of amplified DNA and unre-
solved DNA repair complexes [1,4]. 
The purpose of the “Micronuclei and Disease” special issue is as 
follows:  
• Determine the current level of evidence for association of MN, NPB 
and NBUD with risk of each specific disease including its progression, 
prognosis and genotoxic consequences of therapy and/or its efficacy. 
• Define plausible mechanisms of MN formation that may explain as-
sociation with each disease and evidence that may support it. 
• Identify knowledge gaps and further work needed to justify trans-
lating use of MN, NPB or NBUD measurements into clinical practice. 
It was anticipated that the great majority of data would relate only to 
MN because the adoption of the NPB and NBUD biomarkers occurred 
more than two decades after the lymphocyte cytokinesis block micro-
nucleus (CBMN) assay was first reported in 1984. As a consequence, this 
brief overview is mainly focused on the outcomes relating to MN assays. 
Key aspects to be tackled by each review included:  
• A brief description of the purpose of the review and biological 
plausibility of association of MN, NPB or NBUD with the specific 
disease investigated  
• Narrative review of case-control studies including a summary 
description of all studies in a Table. This table should include in-
formation on number of case and control subjects, outcome measure 
data (MN, NPB, NBUD) expressed as Mean (+/- SEM) in cases and 
controls, Mean Ratio (MR) of MN, NPB and NBUD biomarker data of 
cases relative to controls, including 95 % confidence intervals and P 
values.  
• Prospective studies (if available) are described separately from case- 
control studies in an additional section.  
• Meta-analysis of published data (assuming sufficient studies are 
available and heterogeneity is not too high)  
• Assessment of the potential clinical utility (e.g. triage of patients as 
low/high risk, prognosis, susceptibility to drug genotoxicity etc…) 
and knowledge gaps to translate use of MN, NPB or NBUD into 
clinical practice. 
2. Synopsis and outcomes of individual reviews 
The “MN and Disease” SI includes fourteen papers in addition to this 
one. The first is a review on mechanisms of MN formation and their 
consequences in humans. The following eleven papers are narrative or 
systematic reviews and/or meta-analyses of the association of MN with 
reproduction and child health, inflammation and auto-immune diseases, 
glycation and metabolic diseases, chronic kidney disease, cardiovascular 
disease, eleven different common cancers, ageing and frailty. The 
penultimate paper focuses on the impact of interventions on MN fre-
quency in the elderly. A road map for the translation of MN frequency 
data into clinical practice is the topic of the final paper. Highlights from 
these papers are described below. 
The mechanisms review of Fenech et al. [5] describes the biology of 
the best validated MN assays used in humans namely the lymphocyte 
cytokinesis-block micronucleus (CBMN) cytome assay, the buccal cell 
MN cytome assay and the red blood cell MN assay. Apart from the 
well-established mechanisms of MN formation the review highlighted 
the two most relevant recent discoveries that entrapment of a chromo-
some within a MN leads to two fundamental pathologies (i) shattering of 
the chromosome due to asynchrony between the main nucleus and the 
MN with regards to completion of DNA synthesis and post synthesis 
condensation of chromatin and the subsequent random ligation of the 
fragments to generate a hypermutated chromosome and (ii) the 
pro-inflammatory effect of DNA leakage from MN and NPB with dis-
rupted membranes and shattered chromatin that is sensed by the 
cGAS-STING (cyclic GMP-AMP Synthase-Stimulator of Interferon Genes) 
mechanism. The key point here is that MN and NPB formation leads to 
both chromosome instability and inflammation and explains the asso-
ciation of MN not only with cancer but also other diseases that may be 
driven primarily by excessive inflammation. 
The question of whether DNA damage affects reproductive outcomes 
(i.e. fertility) and whether it is increased in children exposed to envi-
ronmental pollutants and children with common diseases is the focus of 
the review by Knudsen and Kirsch-Volders [6]. Their analysis of the 
available data indicated a consistent increase in MN frequency of lym-
phocytes from infertile adults relative to fertile controls, suggesting the 
possibility that the capacity to produce a sufficient number of functional 
germ cells may be diminished by genotoxic factors that also increase 
genomic instability in lymphocytes. Furthermore, MN frequency was 
also increased in children experiencing common diseases associated 
with more inflammation, and also in children exposed to genotoxic 
pollutants in air and water. The mean ratio (MR) values for MN data in 
lymphocytes and in buccal cells are illustrated in Figs. 1A and 2  
respectively. The authors recommended that larger studies are needed to 
verify these results and also emphasised the practical utility of the 
minimally invasive buccal cell MN assay when performing studies with 
children. 
Sensing of foreign and self-DNA in the cytoplasm triggers the innate 
immune system within cells to increase interferon and cytokine pro-
duction resulting in a pro-inflammatory, autoimmune, and pro-oxidant 
microenvironment that can increase chromosomal instability. The sys-
tematic review and meta-analysis of Kirsch-Volders et al. [7] accumu-
lated and analysed lymphocyte and buccal MN data from studies of 
diseases in which inflammation and auto-immunity play an important 
role in their aetiology. The great majority of the studies showed MR 
values greater than 1.0. Metanalysis of data from diseases with multiple 
studies found a significant increase in MN in cases compared to controls. 
The cases to controls ratio of mean MN frequency was higher in buccal 
cells when compared to lymphocytes suggesting that buccal cell MN 
frequency may be a more sensitive biomarker of DNA damage in people 
with excessive inflammation and auto-immune disorders. 
Deo et al. [8] focused their review on diseases characterised by 
elevated levels of advanced glycation end-products (AGEs) and glycated 
haemoglobin (HbA1c). They reported that lymphocyte and buccal MN 
frequency was significantly elevated (MR = 1.74, P = 0.0003; MR =
2.86, P = 0.02, respectively) in these diseases. However, there was a lack 
of significant correlation between the MR for MN and MR for AGEs or 
HbA1c (measured in the same studies) which suggested that the 
case-control studies investigated may have been confounded by other 
variables that affect MN frequency or disease status. 
A related review by Franzke et al. [9] specifically examined the 
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frequency of MN in overweight, obese and diabetic cases in comparison 
to healthy controls. The studies on overweight and/or obese subjects 
were insufficient for meta-analysis but there was a tendency for MN in 
lymphocytes to be elevated in those with body mass index (BMI) values 
above the normal range. Meta-analysis of lymphocyte MN data from 
type 1 and type 2 diabetics showed a highly significant increment in MN 
for the latter (P < 0.00001) but only marginal for the former (P < 0.04). 
They also reported on MN data with buccal cells from a subset of 4 
studies all of which indicated elevated MN in cases suggesting the po-
tential suitability of this cell type for such studies. Preliminary data on 
NPB and NBUD in lymphocytes showed similar trends as MN in 
diabetics. 
Chronic kidney disease (CKD) is a growing problem in aging pop-
ulations world-wide particularly in those with diabetes given that 30–40 
% are likely to experience CKD. The aetiology of CKD is complex but it is 
plausible that either DNA damage predisposes to CKD initiation or 
progression or that CKD leads to the accumulation of metabolic geno-
toxins such as homocysteine [10]. Stopper et al. [11] reviewed the pa-
pers that have explored the association of MN frequency with CKD in 
both the predialysis or hemodialysis state of the disease. The results of 
their meta-analysis showed that DNA damage measured by both the 
lymphocyte and buccal micronucleus assay is consistently increased 
relative to healthy controls. They also reported that MN frequency in 
CKD patients may be modulated by specific medications and micro-
nutrients suggesting that measuring MN in these patients may be useful 
both as an indicator of disease progression and/or therapeutic efficacy. 
Coronary artery disease (CAD) is a leading cause of mortality and 
there is mounting evidence that DNA damage plays an important role in 
the development of plaques that cause this affliction [12]. In their re-
view and meta-analysis Andreassi et al. [13] identified eight studies that 
investigated the association of lymphocyte MN with CAD and with 
severity of the disease. MN frequency was generally increased in CAD 
patients (P = 0.009) and MN levels were further elevated with higher 
disease severity (P = 0.06− 0.08). There was considerable heterogeneity 
between the studies and for this reason the authors advised that larger 
and more robust studies are required to control variables that may in-
fluence the observed results (e.g type of medication, other complicating 
pathologies) and to improve the evidence that the MN biomarker can be 
clinically useful in identifying vulnerable CAD cases. 
Fig. 1A illustrates the MR results for all of the above (non-cancer) 
diseases that had MN frequency data measured in lymphocytes. Fig. 2 
illustrates MR data for the above (non-cancer) diseases in which MN in 
buccal cells were measured. These data are also described in detail in 
Supplementary Tables 1A and 2. 
Four of the papers in the special issue (Bolognesi et al. [14], Asanov 
et al. [15], Setayesh et al. [16] and Dhillon et al. [17]) focus on MN data 
of cancer cases relative to controls. These papers covered MN data from 
studies involving 11 of the most common cancers and also two inflam-
matory diseases that are associated with increased risk of cancer. 
The review of Bolognesi et al. [14] examines the association of MN 
frequency with head and neck cancers and breast cancer. 81 % of the 
studies on head and neck cancers measured MN in buccal cells and of 
these 71 % investigated the association of buccal MN with oral cancer. 
Buccal MN were significantly increased in oral cancer cases relative to 
controls (meta-MR = 4.71) and in other head and neck cancer cases 
(meta-MR = 2.28); similar increments were observed in studies using 
lymphocyte MN assay. With regards to breast cancer, MN frequency in 
both lymphocytes and buccal cells was increased in cases relative to 
controls (meta-MR = 1.90, meta-MR = 3.89, respectively). Family his-
tory of breast cancer or carriage of BRCA1/2 mutation did not signifi-
cantly affect base-line MN or radiation-induced MN in ex vivo 
lymphocyte cultures. These data suggested that the buccal MN assay 
Fig. 1. [A] Mean Ratio (MR) of lymphocyte MN values for non-cancer disease cases relative to controls. [B] Mean Ratio (MR) of lymphocyte MN values for cancer 
and cancer-related disease cases relative to controls. Error bars represent standard error of the mean. IBD, inflammatory bowel disease; COPD, chronic obstructive 
pulmonary disease. 
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appears to provide the more promising results which supports further 
exploration of its clinical utility in identifying subjects with higher risk 
of head and neck or breast cancer cases. 
There is growing interest for discovering biomarkers to identify 
subjects who may be abnormally susceptible to develop lung cancer. 
Asanov et al. [15] report the results of a review and meta-analysis on 
data from 17 studies regarding the relationship between MN frequency 
and lung cancer; they also explored the relationship of MN with chronic 
obstructive pulmonary disease (COPD), a condition that predisposes to 
lung cancer, using results from 4 studies. Fifteen of the 17 studies on 
lung cancer indicated that lymphocyte MN frequencies that were greater 
in cases compared to controls (meta-MR = 1.82) and all of the 4 COPD 
studies had MR > 1 in cases relative to controls (meta-MR = 1.50). Only 
3 studies reported results with buccal cells in lung cancer cases and 
controls but all had MR values >1 (meta-MR = 1.62). The results 
confirmed the consistency of the association of lymphocyte MN with 
lung cancer risk but further work is required to consolidate the results 
with buccal cells which are particularly relevant given that they are 
located within the aero-digestive tract. 
Setayesh et al. [16] focused their review on the diagnostic relevance 
of MN in urine-derived cells (UDC) and cervix-derived cells (CDC) with 
regards to cancer of the cervix and of the urothelium (i.e. bladder), 
respectively. They reviewed 16 relevant studies and found that a strong 
direct relationship exists between MN frequency and microbial in-
fections, the presence of cancer in the cervix or bladder and the stage of 
cancer in the cervix. The meta-MR for MN frequency in CDC in cervical 
carcinoma cases relative to controls, from 18 studies, was calculated to 
be 8.83 (p = 0.0000) in an earlier analysis (Setayesh et al. [18]). Their 
evaluation of the available data shows that MN are useful additional 
biomarkers for the detection and prognosis of cervical cancer and 
possibly also for bladder cancer. However, better standardisation of the 
UDC and CDC MN assay methodology is essential before translation into 
clinical practice becomes possible. 
In a similar MN and cancer study, Dhillon et al. [17]) analysed the 
relevant data with regards to the association of lymphocyte MN in skin, 
haematological, prostate, colorectal and oesophageal cancer cases as 
compared to healthy controls. Based on data from 19 studies significant 
increases in lymphocyte MN frequency was observed for subjects with 
blood cancers (MR = 3.98; p < 0.0001) and colorectal cancer (MR =
2.69; p < 0.0001) but MR was not significantly increased in prostate, 
skin and oesophageal cancer. They also investigated inflammatory 
bowel disease (IBD) because it increases colorectal cancer risk but found 
no significant association with lymphocyte MN frequency. More studies 
are needed to further verify and consolidate the degree of associations of 
lymphocyte MN with the cancers and IBD investigated in this review and 
meta-analysis. 
Fig. 1B illustrates the MR data for all of the above cancers and cancer- 
related diseases that had MN frequency measured in lymphocytes. Fig. 2 
illustrates MR results for the above cancers in which MN in buccal cells 
were measured, with the exception of the cervical carcinoma and 
bladder cancer data which were obtained using MN assay in cervix and 
urothelial derived cells, respectively. These data are also described in 
detail in Supplementary Tables 1B and 2. 
3. Comparison of MR values for MN frequency in lymphocytes 
and exfoliated epithelial cells in cancer and non-cancer diseases 
Some notable trends in the MR values for MN frequency and the 
diseases investigated are as follows:  
(i) In all diseases examined, MR values for MN in lymphocytes and 
exfoliated cells (buccal, cervical, urothelial cell) exceed 1.0 with 
the exception of prostate cancer.  
(ii) The mean (SEM) of MR values for MN in lymphocytes are 2.3 
(0.2) and 2.0 (0.3) for non-cancer diseases and cancer respec-
tively. In contrast, the mean (SEM) of MR values for MN in 
exfoliated cells (buccal, cervical, urothelial cell) are 3.6 (0.4) and 
6.1 (1.6) for non-cancer diseases and cancer respectively. The 
mean MR value for MN in exfoliated cells is significantly greater 
than in lymphocytes in cancer cases relative to controls (P =
0.0016) (Fig. 3A, Supplementary Table 3A).  
(iii) The MR values for MN in lymphocytes or exfoliated cells in non- 
cancer diseases fall within a similar range as the corresponding 
MR values for cancers and are not statistically different from each 
other (Fig. 3A, Supplementary Table 3A). This suggests that in-
crease in MN, in the same cell type, is associated with non-cancer 
diseases to a similar extent as their association with cancer.  
(iv) In cancer studies that measured MN in the same tissue in which 
cancer occurs (e.g., lymphocytes for blood cancer, buccal cells for 
oral cancer, cervix cells for cervical cells and urothelial cells for 
bladder cancer) the MR values tended to be higher than those 
studies in which MN were measured in surrogate tissues (i.e. 
lymphocytes and buccal cells for studies comparing MN fre-
quencies in cancers that are either not blood or oral cancers 
respectively). We therefore further stratified the data so that 
comparisons can be made for cancer-related MR values of MN 
between the following three groups (a) MR values for MN fre-
quency in lymphocytes for all cancers excluding blood cancers, 
(b) MR values for MN frequency in exfoliated buccal cells for all 
cancers excluding oral cancers and (c) MR values for those cases 
in which MN were measured in cells from the same tissue in 
which cancer was diagnosed (i.e. lymphocytes for blood cancer, 
buccal cells for oral cancer, cervix cells for cervical cells and 
urothelial cells for bladder cancer). This comparison showed that 
the MR results (mean (SEM)) for the third group (8.4 (1.3)) were 
much higher as compared to the lymphocyte MN and buccal MN 
cancer MR results which were 1.7 (0.1) and 2.6 (0.7) respectively 
with the corresponding statistical significance values being p <
0.0001 and p = 0.0003 (Fig. 3B, Supplementary Table 3B). 
Fig. 2. Mean ratio (MR) of exfoliated epithelial cell MN values in cancer or non-cancer cases relative to controls. Error bars are standard error of the mean.  
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4. The association of MN with ageing and neurodegenerative 
diseases 
Another important aspect of MN assays in lymphocyte and buccal 
cells is their robust incremental association with chronological ageing 
and with and accelerated ageing syndromes [19–24] which is driven by 
mitotic malsegregation of whole chromosomes or chromosome frag-
ments and by the rupture of nucleoplasmic bridges originating from 
dicentric chromosomes [25]. For these reasons there is considerable 
interest to explore whether MN, NPB and NBUD may also be prognostic 
indicators of physical and/or cognitive frailty. In their contribution to 
this special issue Laffon et al. [26] review the evidence and conclude 
that “MN frequency is a suitable biomarker of genomic instability in ageing. 
However, the possible role of NPB as cytogenetic outcomes indicative of the 
ageing process is still unclear and further investigation is required to figure 
this out.”. Furthermore, they discuss the limited evidence from two 
studies exploring the association of MN with frailty and the limitations 
of the study designs that need to be addressed in further studies in this 
emerging field. 
There is also much interest in the association of MN with neurode-
generative diseases which were originally initiated by the work from 
Lucia Migliore’s group showing significant increments in MN frequency 
in Alzheimer’s and Parkinson’s disease cases that were shown to be due 
to chromosome loss in the former and chromosome breakage in the 
latter [24,27]. Further studies by Fenech’s group showed that MN were 
only marginally increased in buccal cells but not in lymphocytes, and 
that in lymphocytes MN, NPB and NBUD were inversely correlated with 
cognitive function measured in healthy controls, mild cognitive 
impairment cases and Alzheimer’s disease cases [24,28]. In a more 
recent and larger study of various neurodegenerative disorders Reimann 
et al. [29] could not find significant associations of buccal MN and other 
related biomarkers (e.g. nuclear buds, binucleated cells) with the disease 
state when compared to controls. These contrasting relationships be-
tween these chromosome instability biomarkers and neurodegenerative 
diseases highlight the need for better study designs to obtain more 
robust data that can be replicated across laboratories. Large heteroge-
neity and paucity of studies since the previous review on this topic [24] 
hindered the possibility of a meta-analytical approach to address the 
question of the association of MN and other nuclear anomalies with 
neurodegenerative diseases such as Alzheimer’s disease. Consequently, 
the review on neurodegenerative diseases and MN has been delayed 
until such time when sufficient consistent comparable data is available 
and for this reason it is not included in this special issue. 
Given the importance of genomic instability in the aetiology of age- 
related disease, one of the reviews of the special issue was dedicated to 
studies that explored the possibility of reducing the level of MN, NPB 
and NBUD by diet and/or lifestyle interventions in the elderly. The 
systematic review of Wagner et al. [30] identified 13 papers describing 
dietary and/or physical activity interventions in the elderly that 
measured MN. Nine of these studies were deemed suitable for 
meta-analysis because they involved a randomised controlled trial 
(RCT), in those 60 years of age or older and the intervention was 
directed towards reducing risk of common age-related diseases or 
micronutrient deficiency and included MN and/or NPB or NBUD in 
lymphocytes or buccal cells as biomarkers of effect. Apart from the tea 
intervention by Li N et al. [31] no other RCT identified in the 
meta-analysis significantly reduced MN in lymphocytes. The same 
intervention [31] also reported significant reductions in MN in buccal 
cells, and so did the antioxidant supplementation studies of Stich et al. 
[32,33]. The lack of effect in the other interventions might have been 
due to limitations of study design such as lack of participant screening 
which is necessary to identify likely responders based on their deficiency 
in the nutrients used in the intervention and, also, on the basis of their 
elevated frequency in MN, because it is generally those who are 
micronutrient deficient and/or exhibit elevated base-line levels of MN 
who respond to intervention. The efficacy of this approach was for 
example demonstrated in a RCT intervention with folic acid and vitamin 
B-12 supplementation in young adults (Fenech et al. [34]) and an RCT of 
zinc carnosine supplementation in apparently healthy elderly subjects 
with low zinc status (Sharif et al. [35]). It is evident that stricter 
Fig. 3. [A] Comparison of mean ratio (MR) values for 
micronuclei (MN) in lymphocytes (LYM) and exfoliated 
epithelial (EXF) cells in non-cancer disease and cancer 
cases relative to controls. LYM MR NON-CANCER =
Lymphocyte micronuclei mean ratio in non-cancer disease 
cases relative to controls. LYM MR CANCER = Lymphocyte 
micronuclei mean ratio in cancer cases relative to controls. 
EXF MR NON-CANCER = Exfoliated epithelial cell micro-
nuclei mean ratio in non-cancer disease cases relative to 
controls. EXF MR CANCER = Exfoliated epithelial cell 
micronuclei mean ratio in cancer cases relative to controls. 
[B] Comparison of mean ratio (MN) values in cancer cases 
relative to controls for (i) MN measured in same tissue as 
that of the cancer (e.g. lymphocytes for blood cancers, 
buccal cells for oral cancer, cervix derived cells for cervical 
cancer, urine derived cells for bladder cancer), (ii) MN 
measured in buccal cells, in cases with cancer (excluding 
oral cancer), (iii) MN measured in lymphocytes in cases 
with cancer (excluding blood cancers). LYM MR CANCER 
(XBC) = Lymphocyte micronuclei mean ratio in cancer 
cases (excluding blood cancers) relative to controls. 
BUCCAL MR CANCER (XOC) = Buccal cell micronuclei 
mean ratio in cancer cases (excluding oral cancer) relative 
to controls. SAME CELLS MR CANCER = MR values for 
cancer cases relative to controls in those cases when MN 
were measured in cells from the same tissue as that of the 
cancer. Error bars represent the standard error of the mean.   
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attention to study design and participant selection is required to obtain 
robust scientific evidence that proves the efficacy of interventions to 
improve genome integrity in both younger and older adults. 
5. Knowledge gaps and future research required to translate MN 
assays into clinical practice 
The final paper of the special issue by Bonassi and Fenech [36] dis-
cusses a roadmap of what is required to validate and translate the 
application of MN assays into clinical practice with the support of health 
care professionals. The proposed roadmap consists of three critical steps:  
(i) Evidence that MN assays can differentiate disease subjects vs 
unaffected individuals at group level using Case-Control studies. 
These studies should also identify important variables such as 
demographic, genetic, environmental, therapeutic and nutrition 
factors that can modify the MN biomarker in healthy and disease 
subjects.  
(ii) Transition of the use of MN assays from application at the group 
level to the individual level. This requires technological advances 
to establish minimally invasive high-throughput MN measure-
ment techniques so that MN assay data at the individual level are 
statistically sufficiently robust to be adequately reliable and 
affordable to be deployed in a clinical setting.  
(iii) Prospective cohort studies and randomised controlled trials to 
verify that MN assays are predictive of disease and that MN fre-
quency modification alters disease outcomes. 
After the realisation of these three critical steps, pragmatic trials will 
also be required to evaluate the usefulness of MN measurements in 
routine clinical practice to provide the decisive evidence to support their 
adoption by the medical and public health community. The review also 
provides examples of MN assays that are currently in clinical practice 
and others for which there is already adequate evidence for considering 
pragmatic trials for their translation into practice. 
A strength of the MR data generated from papers in the SI is the a 
priori definition of common guidelines for the selection of papers, 
including search strategy, acceptability of scoring criteria and avail-
ability of a relevant control population. A potential weakness of the MR 
data generated in the reviews is that most of the reviewed studies used 
only one cell type to determine the association of MN with a particular 
disease. Consequently, comparisons of MN association with disease, 
using MN data from different cell types, involved data that often was not 
from the same individual, which may have increased variability in the 
MN data. Therefore, more studies are needed that also compare MN 
frequency in different tissues from the same individuals to determine 
more robustly the degree of correlation of MN frequency between 
different tissues and, to establish, more reliably, for each tissue the de-
gree of association of MN with important diseases. The relative sensi-
tivity of the association of MN frequency with specific diseases probably 
depends on whether the cells sampled are from a tissue that is directly or 
indirectly exposed to exogenous or endogenous genotoxins that 
contribute to the aetiology of the disease. Fig. 4 illustrates the inter- 
relationship between endogenous/exogenous genotoxin, glycation and 
inflammation exposure and the potential direct or indirect exposure 
routes of tissues for which MN assays have been established. 
Up to now five prospective studies have been reported showing that 
elevated lymphocyte MN frequency predicts cancer risk, cardiovascular 
disease mortality, adverse cardiac events and pregnancy complications 
[37–41]. More prospective studies are needed to consolidate these ob-
servations and also to test whether similar results are obtained using MN 
data from buccal cells and possibly other cell types from the tissue where 
the disease occurs. Ideally, as a minimum, future prospective studies 
should include data for both lymphocyte and buccal MN frequency from 
the same individual. 
6. Conclusions 
This special issue is an important milestone in the evidence sup-
porting the application of MN as a plausible genomic biomarker of 
developmental and degenerative disease risk. There is now an abun-
dance of evidence from case-control studies that MN in lymphocytes 
measured using the cytokinesis-block MN assay in lymphocytes and 
conventional MN assay in buccal cells is substantially elevated in both 
non-cancer diseases and in the great majority of cancers. Based on the 
MR data evaluated in this SI, the association of MN in buccal cells with 
disease appears to be as robust as MN in lymphocytes. Furthermore, 
measuring MN in the tissue in which cancer arises is more strongly 
Fig. 4. Flow diagram of inter-relationship between endogenous/exogenous genotoxin, glycation and inflammation exposure and their sequential impact on 
micronucleus (MN) formation in tissues for which MN assays have been established (BUC MN, micronuclei in buccal cells; CDC MN, micronuclei in cervix derived 
cells; LYMN MN, micronuclei in lymphocytes; RBC MN, red blood cell micronuclei; UDC MN, micronuclei in urine derived cells). Other factors not shown in the 
diagram that influence MN formation include genetic susceptibility to genotoxin-induced micronuclei and the aggravating effect of deficiency in certain micro-
nutrients (e.g. folate, vitamin B-12 and zinc deficiency) that are required for DNA replication and repair and are known to increase MN formation when their supply 
is inadequate. 
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associated with cancer risk than measuring MN in surrogate tissue, 
however, this is an approach that may only be practical in the clinical 
setting depending on the location and accessibility of the cancer being 
investigated. These important advances underscore the need to identify 
the diseases where current evidence suggests the best chance of success 
in translating MN assays into practice and to develop appropriate study 
designs to achieve these purposes. 
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